TI
REGN icon

tru Independence’s Regeneron Pharmaceuticals REGN Stock Holding History

tru Independence’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12
Closed -$5 – 618
2020
Q4 		$5 Buy
12
+3
+33% +$1.62K ﹤0.01% 612
2020
Q3 		$5K Sell
9
-15
-63% -$9.1K ﹤0.01% 299
2020
Q2 		$15 Hold
24
– – ﹤0.01% 543
2020
Q1 		$11 Hold
24
– – ﹤0.01% 428
2019
Q4 		$11K Buy
+24
New +$8.07K ﹤0.01% 555

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

tru Independence's REGN Position: Q1 2021 in Review

tru Independence sold out of Regeneron Pharmaceuticals (REGN) in Q1 2021, closing a stake of 12 shares — an estimated $5 sold.

tru Independence first reported a position in REGN in Q4 2019 and held it in 5 quarters. The position peaked at $11K in Q4 2019. 924 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

  • tru Independence reported no remaining Regeneron Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • tru Independence sold 12 Regeneron Pharmaceuticals shares in Q1 2021, an estimated $5.
  • tru Independence first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • tru Independence's Regeneron Pharmaceuticals position peaked at $11K in Q4 2019.
  • 924 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on tru Independence's 13F filing for Q1 2021, filed 20 May 2021.